| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 32 | 2025 | 237 | 7.410 |
Why?
|
| Coronary Artery Disease | 32 | 2025 | 768 | 5.800 |
Why?
|
| Coronary Artery Bypass | 19 | 2024 | 514 | 4.020 |
Why?
|
| ST Elevation Myocardial Infarction | 14 | 2024 | 110 | 3.180 |
Why?
|
| Transcatheter Aortic Valve Replacement | 15 | 2024 | 202 | 3.060 |
Why?
|
| Acute Coronary Syndrome | 12 | 2025 | 211 | 2.930 |
Why?
|
| Aortic Valve Stenosis | 14 | 2024 | 338 | 2.840 |
Why?
|
| Coronary Angiography | 18 | 2025 | 428 | 2.360 |
Why?
|
| Drug-Eluting Stents | 7 | 2019 | 55 | 2.340 |
Why?
|
| Myocardial Infarction | 20 | 2024 | 1022 | 2.060 |
Why?
|
| Hospital Mortality | 14 | 2024 | 1027 | 2.020 |
Why?
|
| Stroke | 16 | 2024 | 986 | 1.630 |
Why?
|
| Coronary Stenosis | 4 | 2025 | 73 | 1.570 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2012 | 174 | 1.450 |
Why?
|
| Electrocardiography | 8 | 2024 | 974 | 1.440 |
Why?
|
| Treatment Outcome | 58 | 2024 | 12342 | 1.330 |
Why?
|
| Atrial Fibrillation | 8 | 2024 | 661 | 1.300 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 880 | 1.290 |
Why?
|
| Registries | 11 | 2023 | 1422 | 1.260 |
Why?
|
| Postoperative Complications | 14 | 2024 | 3068 | 1.240 |
Why?
|
| Risk Factors | 50 | 2024 | 10272 | 1.220 |
Why?
|
| Peripheral Arterial Disease | 5 | 2024 | 290 | 1.210 |
Why?
|
| Myocardial Revascularization | 7 | 2024 | 100 | 1.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 9 | 2024 | 439 | 1.200 |
Why?
|
| Coronary Vessels | 7 | 2025 | 540 | 1.180 |
Why?
|
| Humans | 151 | 2025 | 124797 | 1.080 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2020 | 367 | 1.080 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2024 | 265 | 1.050 |
Why?
|
| Cardiovascular Diseases | 15 | 2024 | 1943 | 1.040 |
Why?
|
| Stents | 5 | 2024 | 882 | 0.980 |
Why?
|
| Metal Nanoparticles | 2 | 2022 | 42 | 0.960 |
Why?
|
| Aged | 54 | 2024 | 19691 | 0.950 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2024 | 733 | 0.900 |
Why?
|
| Catheterization, Peripheral | 2 | 2023 | 126 | 0.870 |
Why?
|
| Shock, Cardiogenic | 7 | 2024 | 193 | 0.850 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2021 | 243 | 0.840 |
Why?
|
| Daucus carota | 1 | 2022 | 3 | 0.810 |
Why?
|
| Fibrinolytic Agents | 3 | 2024 | 199 | 0.810 |
Why?
|
| Zinc Oxide | 1 | 2022 | 7 | 0.810 |
Why?
|
| Coronary Vessel Anomalies | 6 | 2024 | 278 | 0.800 |
Why?
|
| Middle Aged | 55 | 2024 | 26717 | 0.780 |
Why?
|
| Aortic Valve | 11 | 2024 | 443 | 0.770 |
Why?
|
| Risk Assessment | 17 | 2024 | 3435 | 0.760 |
Why?
|
| Atrial Appendage | 1 | 2021 | 46 | 0.730 |
Why?
|
| Vascular Diseases | 4 | 2024 | 167 | 0.730 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 134 | 0.730 |
Why?
|
| Angioplasty, Balloon | 1 | 2022 | 168 | 0.730 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 204 | 0.730 |
Why?
|
| Ultrasonography, Interventional | 4 | 2024 | 193 | 0.720 |
Why?
|
| Male | 74 | 2024 | 61285 | 0.700 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2022 | 157 | 0.690 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2019 | 22 | 0.690 |
Why?
|
| Heart Transplantation | 2 | 2021 | 862 | 0.690 |
Why?
|
| Stroke Volume | 6 | 2023 | 481 | 0.660 |
Why?
|
| Female | 76 | 2024 | 66555 | 0.650 |
Why?
|
| Ultrasonic Therapy | 1 | 2019 | 31 | 0.650 |
Why?
|
| Cause of Death | 4 | 2024 | 472 | 0.650 |
Why?
|
| Drug Utilization | 2 | 2020 | 162 | 0.640 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 506 | 0.640 |
Why?
|
| Atherosclerosis | 6 | 2024 | 910 | 0.630 |
Why?
|
| Colchicine | 3 | 2021 | 43 | 0.630 |
Why?
|
| Hemorrhage | 8 | 2025 | 466 | 0.630 |
Why?
|
| Cardiac Catheterization | 8 | 2023 | 631 | 0.630 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 1108 | 0.610 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 111 | 0.610 |
Why?
|
| Seasons | 3 | 2005 | 311 | 0.600 |
Why?
|
| Inpatients | 5 | 2022 | 500 | 0.590 |
Why?
|
| Echocardiography | 8 | 2020 | 1052 | 0.580 |
Why?
|
| Heart Septum | 2 | 2009 | 55 | 0.580 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 6521 | 0.560 |
Why?
|
| Pericarditis | 2 | 2020 | 43 | 0.560 |
Why?
|
| United States | 28 | 2024 | 10886 | 0.550 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 178 | 0.550 |
Why?
|
| Cocaine | 1 | 2018 | 207 | 0.530 |
Why?
|
| Ethanol | 2 | 2009 | 163 | 0.530 |
Why?
|
| Femoral Artery | 4 | 2023 | 194 | 0.520 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2022 | 1111 | 0.520 |
Why?
|
| Retrospective Studies | 25 | 2024 | 16299 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2023 | 727 | 0.510 |
Why?
|
| Time Factors | 15 | 2024 | 6309 | 0.500 |
Why?
|
| Anticoagulants | 5 | 2025 | 592 | 0.490 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 201 | 0.490 |
Why?
|
| Propensity Score | 3 | 2021 | 213 | 0.480 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 122 | 0.480 |
Why?
|
| Catheter Ablation | 2 | 2009 | 238 | 0.480 |
Why?
|
| Obesity | 5 | 2024 | 2278 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 4 | 2024 | 1265 | 0.440 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 108 | 0.440 |
Why?
|
| Hypertension | 5 | 2023 | 1314 | 0.420 |
Why?
|
| Drug Prescriptions | 5 | 2020 | 221 | 0.420 |
Why?
|
| Tomography, Optical Coherence | 3 | 2024 | 523 | 0.420 |
Why?
|
| Hyperlipidemias | 3 | 2024 | 175 | 0.410 |
Why?
|
| Medication Adherence | 4 | 2021 | 401 | 0.400 |
Why?
|
| Adult | 32 | 2024 | 29472 | 0.400 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2023 | 158 | 0.400 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2025 | 43 | 0.390 |
Why?
|
| Saphenous Vein | 1 | 2012 | 60 | 0.390 |
Why?
|
| Sex Factors | 7 | 2021 | 1285 | 0.380 |
Why?
|
| Vascular Grafting | 1 | 2012 | 46 | 0.380 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2021 | 14 | 0.370 |
Why?
|
| Incidental Findings | 2 | 2009 | 124 | 0.370 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 745 | 0.360 |
Why?
|
| Logistic Models | 5 | 2021 | 1810 | 0.360 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 632 | 0.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 224 | 0.350 |
Why?
|
| Heart Failure | 7 | 2023 | 2302 | 0.350 |
Why?
|
| Feces | 2 | 2005 | 717 | 0.350 |
Why?
|
| Severity of Illness Index | 10 | 2025 | 2903 | 0.340 |
Why?
|
| Renal Insufficiency | 2 | 2011 | 236 | 0.340 |
Why?
|
| Sex Characteristics | 1 | 2012 | 319 | 0.330 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 263 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 723 | 0.320 |
Why?
|
| Heart Valve Prosthesis | 2 | 2023 | 301 | 0.320 |
Why?
|
| Odds Ratio | 4 | 2020 | 1252 | 0.320 |
Why?
|
| Sclerotherapy | 1 | 2009 | 40 | 0.310 |
Why?
|
| Vena Cava, Superior | 1 | 2009 | 56 | 0.310 |
Why?
|
| Tyrosine | 1 | 2009 | 151 | 0.310 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 121 | 0.300 |
Why?
|
| Sarcoidosis | 1 | 2009 | 61 | 0.300 |
Why?
|
| Survival Rate | 6 | 2024 | 2035 | 0.300 |
Why?
|
| Heart Arrest | 2 | 2023 | 351 | 0.290 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 129 | 0.270 |
Why?
|
| Comorbidity | 8 | 2024 | 1531 | 0.260 |
Why?
|
| Pakistan | 9 | 2009 | 77 | 0.260 |
Why?
|
| Coronary Circulation | 2 | 2019 | 211 | 0.260 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 1163 | 0.250 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 5153 | 0.250 |
Why?
|
| Radial Artery | 2 | 2023 | 27 | 0.250 |
Why?
|
| Computed Tomography Angiography | 2 | 2025 | 198 | 0.250 |
Why?
|
| Spasm | 2 | 2023 | 49 | 0.250 |
Why?
|
| Diastole | 3 | 2020 | 170 | 0.250 |
Why?
|
| Morbidity | 2 | 2019 | 244 | 0.240 |
Why?
|
| Age Factors | 3 | 2021 | 2817 | 0.240 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 443 | 0.240 |
Why?
|
| Guideline Adherence | 4 | 2020 | 382 | 0.240 |
Why?
|
| Hirudins | 1 | 2025 | 37 | 0.240 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 50 | 0.240 |
Why?
|
| Life Style | 3 | 2023 | 415 | 0.230 |
Why?
|
| Mitral Valve | 2 | 2023 | 247 | 0.230 |
Why?
|
| Vibrio cholerae | 1 | 2004 | 27 | 0.230 |
Why?
|
| Embolic Protection Devices | 1 | 2024 | 8 | 0.230 |
Why?
|
| Cholera | 1 | 2004 | 26 | 0.230 |
Why?
|
| Hematoma | 2 | 2023 | 93 | 0.230 |
Why?
|
| Prognosis | 9 | 2022 | 4607 | 0.230 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 68 | 0.230 |
Why?
|
| Global Burden of Disease | 1 | 2024 | 25 | 0.230 |
Why?
|
| Intracranial Embolism | 1 | 2024 | 27 | 0.230 |
Why?
|
| Prevalence | 7 | 2024 | 2451 | 0.230 |
Why?
|
| Simvastatin | 1 | 2024 | 76 | 0.230 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2005 | 87 | 0.230 |
Why?
|
| Thiophenes | 2 | 2014 | 60 | 0.230 |
Why?
|
| Heart Valve Diseases | 2 | 2017 | 171 | 0.220 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 218 | 0.220 |
Why?
|
| Body Mass Index | 2 | 2021 | 1568 | 0.220 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 528 | 0.220 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 489 | 0.220 |
Why?
|
| Secondary Prevention | 3 | 2021 | 217 | 0.220 |
Why?
|
| Databases, Factual | 6 | 2024 | 1180 | 0.220 |
Why?
|
| Prescription Drugs | 2 | 2014 | 54 | 0.220 |
Why?
|
| Models, Cardiovascular | 1 | 2025 | 181 | 0.220 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 39 | 0.220 |
Why?
|
| Mortality | 5 | 2024 | 236 | 0.220 |
Why?
|
| Warfarin | 2 | 2021 | 119 | 0.210 |
Why?
|
| Heparin | 1 | 2025 | 229 | 0.210 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 104 | 0.210 |
Why?
|
| Heart-Assist Devices | 2 | 2022 | 1053 | 0.210 |
Why?
|
| Coronary Occlusion | 1 | 2023 | 27 | 0.210 |
Why?
|
| No-Reflow Phenomenon | 2 | 2019 | 9 | 0.210 |
Why?
|
| Health Status Disparities | 2 | 2024 | 227 | 0.200 |
Why?
|
| Reducing Agents | 1 | 2022 | 2 | 0.200 |
Why?
|
| Piperazines | 2 | 2014 | 238 | 0.200 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2022 | 31 | 0.200 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2022 | 42 | 0.200 |
Why?
|
| Popliteal Artery | 1 | 2022 | 54 | 0.200 |
Why?
|
| X-Ray Diffraction | 1 | 2022 | 96 | 0.200 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 872 | 0.200 |
Why?
|
| Machine Learning | 1 | 2025 | 242 | 0.200 |
Why?
|
| Silver | 1 | 2022 | 22 | 0.190 |
Why?
|
| Vascular Patency | 1 | 2022 | 213 | 0.190 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 112 | 0.190 |
Why?
|
| Conservative Treatment | 1 | 2021 | 33 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1272 | 0.190 |
Why?
|
| Marijuana Use | 1 | 2021 | 8 | 0.190 |
Why?
|
| Unsafe Sex | 1 | 2021 | 22 | 0.190 |
Why?
|
| Smoking | 2 | 2024 | 1044 | 0.190 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 39 | 0.180 |
Why?
|
| Bacteria | 3 | 2009 | 484 | 0.180 |
Why?
|
| Endocarditis, Bacterial | 3 | 2009 | 133 | 0.180 |
Why?
|
| Aspirin | 3 | 2022 | 226 | 0.180 |
Why?
|
| Plant Extracts | 1 | 2022 | 122 | 0.180 |
Why?
|
| Vaping | 1 | 2021 | 29 | 0.180 |
Why?
|
| Time | 1 | 2021 | 94 | 0.180 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2021 | 93 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2025 | 779 | 0.180 |
Why?
|
| Length of Stay | 4 | 2024 | 1309 | 0.180 |
Why?
|
| Predictive Value of Tests | 6 | 2025 | 2142 | 0.180 |
Why?
|
| Veterans Health | 2 | 2020 | 176 | 0.180 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 46 | 0.180 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2020 | 8 | 0.180 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 59 | 0.170 |
Why?
|
| Age of Onset | 2 | 2021 | 582 | 0.170 |
Why?
|
| Bioprosthesis | 1 | 2021 | 115 | 0.170 |
Why?
|
| Radiotherapy | 1 | 2020 | 136 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2022 | 290 | 0.170 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2023 | 255 | 0.170 |
Why?
|
| Endocarditis | 1 | 2020 | 105 | 0.160 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 973 | 0.160 |
Why?
|
| Prescriptions | 1 | 2019 | 40 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 102 | 0.160 |
Why?
|
| Microcirculation | 1 | 2019 | 93 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 790 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 431 | 0.160 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 435 | 0.160 |
Why?
|
| Pneumonia | 2 | 2020 | 326 | 0.160 |
Why?
|
| Leukocyte Count | 1 | 2019 | 250 | 0.160 |
Why?
|
| Global Health | 2 | 2024 | 558 | 0.160 |
Why?
|
| Fluoroscopy | 1 | 2019 | 91 | 0.160 |
Why?
|
| Office Visits | 1 | 2019 | 77 | 0.160 |
Why?
|
| Alcoholism | 1 | 2021 | 231 | 0.160 |
Why?
|
| Pain | 1 | 2022 | 459 | 0.150 |
Why?
|
| Multimorbidity | 1 | 2018 | 20 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 188 | 0.150 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 85 | 0.150 |
Why?
|
| Bisoprolol | 1 | 2018 | 10 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 671 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 427 | 0.150 |
Why?
|
| Hospitalization | 3 | 2023 | 1783 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 197 | 0.150 |
Why?
|
| Atenolol | 1 | 2018 | 43 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 70 | 0.150 |
Why?
|
| Propanolamines | 1 | 2018 | 32 | 0.150 |
Why?
|
| Metoprolol | 1 | 2018 | 22 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2019 | 283 | 0.150 |
Why?
|
| Primary Prevention | 2 | 2021 | 168 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 4783 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2020 | 261 | 0.150 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 357 | 0.150 |
Why?
|
| Diabetic Angiopathies | 2 | 2021 | 65 | 0.150 |
Why?
|
| Propranolol | 1 | 2018 | 128 | 0.150 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2017 | 6 | 0.140 |
Why?
|
| Incretins | 1 | 2018 | 25 | 0.140 |
Why?
|
| Chest Pain | 1 | 2018 | 124 | 0.140 |
Why?
|
| Cell Survival | 1 | 2020 | 807 | 0.140 |
Why?
|
| Texas | 5 | 2024 | 3590 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2020 | 230 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 478 | 0.140 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 63 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2017 | 27 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 354 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 834 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 106 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 90 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2020 | 366 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 464 | 0.130 |
Why?
|
| Balloon Valvuloplasty | 1 | 2016 | 25 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1674 | 0.130 |
Why?
|
| Incidence | 5 | 2024 | 3144 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1247 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2019 | 1495 | 0.130 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3448 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2024 | 682 | 0.130 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2017 | 142 | 0.130 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 135 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2424 | 0.120 |
Why?
|
| Pericardial Window Techniques | 1 | 2015 | 6 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.120 |
Why?
|
| Cardiac Tamponade | 1 | 2015 | 37 | 0.120 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 65 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2020 | 855 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2015 | 6137 | 0.110 |
Why?
|
| Cardiology | 1 | 2019 | 502 | 0.110 |
Why?
|
| Subclavian Artery | 1 | 2014 | 74 | 0.110 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2013 | 38 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2019 | 774 | 0.110 |
Why?
|
| Preoperative Care | 2 | 2012 | 351 | 0.110 |
Why?
|
| Stellate Ganglion | 1 | 2013 | 9 | 0.110 |
Why?
|
| Tachycardia, Sinus | 1 | 2013 | 7 | 0.110 |
Why?
|
| Adolescent | 7 | 2024 | 19329 | 0.100 |
Why?
|
| Systole | 1 | 2013 | 198 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1105 | 0.100 |
Why?
|
| Bundle-Branch Block | 2 | 2023 | 35 | 0.100 |
Why?
|
| Hospitals, University | 4 | 2009 | 97 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 225 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 171 | 0.100 |
Why?
|
| Biomarkers | 3 | 2020 | 3063 | 0.100 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 265 | 0.100 |
Why?
|
| Anesthetics, Local | 1 | 2013 | 81 | 0.100 |
Why?
|
| Standard of Care | 1 | 2013 | 130 | 0.100 |
Why?
|
| Nerve Block | 1 | 2013 | 65 | 0.100 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 101 | 0.100 |
Why?
|
| Metals | 1 | 2012 | 62 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 444 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1091 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1038 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2090 | 0.090 |
Why?
|
| Culture Media | 2 | 2009 | 182 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1664 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 86 | 0.090 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 222 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 661 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1090 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 105 | 0.080 |
Why?
|
| Child, Preschool | 5 | 2020 | 14050 | 0.080 |
Why?
|
| Consensus | 1 | 2013 | 634 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 267 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2019 | 1348 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2024 | 383 | 0.080 |
Why?
|
| Syndrome | 1 | 2012 | 1118 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2013 | 689 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 8987 | 0.080 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 60 | 0.080 |
Why?
|
| Platelet-Rich Plasma | 1 | 2009 | 15 | 0.080 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 61 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2009 | 57 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 232 | 0.080 |
Why?
|
| Syncope | 1 | 2009 | 52 | 0.080 |
Why?
|
| Bacterial Infections | 2 | 2009 | 305 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2009 | 147 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 161 | 0.070 |
Why?
|
| Aortography | 1 | 2009 | 199 | 0.070 |
Why?
|
| DNA | 1 | 2013 | 1600 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2509 | 0.070 |
Why?
|
| Reoperation | 2 | 2021 | 833 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 201 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 585 | 0.070 |
Why?
|
| Creatinine | 1 | 2009 | 390 | 0.070 |
Why?
|
| Osteomalacia | 1 | 2006 | 7 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 368 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1351 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 2880 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2009 | 365 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2006 | 95 | 0.060 |
Why?
|
| Hip Fractures | 1 | 2006 | 67 | 0.060 |
Why?
|
| Hydrodynamics | 1 | 2025 | 25 | 0.060 |
Why?
|
| Biopsy | 1 | 2009 | 1239 | 0.060 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2004 | 8 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2788 | 0.060 |
Why?
|
| Antithrombins | 1 | 2025 | 56 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 598 | 0.060 |
Why?
|
| Infant | 3 | 2005 | 12483 | 0.060 |
Why?
|
| Serotyping | 1 | 2004 | 178 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2625 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2024 | 60 | 0.050 |
Why?
|
| Hypertension, Portal | 1 | 2004 | 78 | 0.050 |
Why?
|
| Age Distribution | 1 | 2024 | 415 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2023 | 5 | 0.050 |
Why?
|
| Intermittent Claudication | 1 | 2024 | 58 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2024 | 301 | 0.050 |
Why?
|
| Algorithms | 1 | 2010 | 1616 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2024 | 179 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2006 | 301 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 632 | 0.050 |
Why?
|
| Health Resources | 1 | 2024 | 116 | 0.050 |
Why?
|
| Students, Nursing | 1 | 2002 | 19 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 121 | 0.050 |
Why?
|
| Anorexia | 1 | 2002 | 27 | 0.050 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 6 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1813 | 0.050 |
Why?
|
| Agriculture | 1 | 2022 | 29 | 0.050 |
Why?
|
| Mitral Valve Stenosis | 1 | 2021 | 35 | 0.050 |
Why?
|
| Triglycerides | 1 | 2024 | 573 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 187 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2006 | 767 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2006 | 930 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2002 | 75 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2021 | 13 | 0.050 |
Why?
|
| Suicide, Assisted | 1 | 2001 | 11 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2025 | 1393 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2021 | 25 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 52 | 0.050 |
Why?
|
| Child | 4 | 2020 | 24454 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2021 | 133 | 0.050 |
Why?
|
| Diarrhea | 1 | 2003 | 316 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 107 | 0.040 |
Why?
|
| Patient Selection | 2 | 2016 | 693 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2021 | 94 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 50 | 0.040 |
Why?
|
| Attitude | 1 | 2001 | 115 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2021 | 428 | 0.040 |
Why?
|
| Ischemia | 1 | 2024 | 357 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2023 | 686 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 13 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 88 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2020 | 45 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2020 | 55 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2003 | 348 | 0.040 |
Why?
|
| Angina, Stable | 1 | 2019 | 4 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 293 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 49 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 422 | 0.040 |
Why?
|
| Pyridones | 1 | 2020 | 112 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2021 | 298 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 222 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2019 | 89 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 731 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 174 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 82 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1028 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 344 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 94 | 0.040 |
Why?
|
| Veterans | 2 | 2021 | 1757 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 724 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 536 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 143 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 809 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 1425 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 307 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 107 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 385 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 568 | 0.040 |
Why?
|
| Students, Medical | 1 | 2002 | 356 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3587 | 0.030 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2018 | 146 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 952 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 521 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 176 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 672 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2018 | 150 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 68 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 248 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 387 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1691 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1596 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 747 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2044 | 0.030 |
Why?
|
| Animals | 3 | 2022 | 34186 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 283 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1136 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 496 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1428 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 7172 | 0.020 |
Why?
|
| Kidney | 1 | 2018 | 1354 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 334 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 503 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3142 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 3010 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1425 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 165 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 479 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2009 | 242 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 2557 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4542 | 0.020 |
Why?
|
| Blood | 1 | 2004 | 105 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1894 | 0.010 |
Why?
|
| Family Practice | 1 | 2001 | 90 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 105 | 0.010 |
Why?
|